Reuters logo
Pharmacyclics cancer drug not approvable--US FDA
December 22, 2007 / 12:19 AM / 10 years ago

Pharmacyclics cancer drug not approvable--US FDA

LOS ANGELES, Dec 21 (Reuters) - Drug developer Pharmacyclics Inc PCYC.O said on Friday that the U.S. Food and Drug Administration turned down its application to market Xcytrin as a treatment for non-small cell lung cancer which has spread to the brain.

The company said in a statement that it continues to believe that Xcytrin is a novel active cancer drug and will seek a corporate partner to help support future development.

Pharmacyclics said it expects data in the first half of 2008 from three Phase 2 trials evaluating the drug in patients with advanced relapsed non-small cell lung cancer.

The company had been seeking approval for use of Xcytrin in combination with whole brain radiation therapy. (Reporting by Deena Beasley in Los Angeles; Editing by Gary Hill)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below